Outstanding Questions Regarding Induced Pluripotent Stem (Ips) Cell Research

Miguel A. Esteban,Jiekai Chen,Jiayin Yang,Feng Li,Wen Li,Duanqing Pei
2010-01-01
Abstract:Terminal somatic cell differentiation is not irreversible. The same route that transforms embryonic stem cells (ESCs) into specific lineages can be walked backwards, e.g. by means of the "induced pluripotent stem (iPS) cell" technology discovered by Shinya Yamanaka in 2006. The implications of iPS are out of proportion and its ease and reproducibility has made it a favorite option compared to other existing approaches including cell fusion or somatic cell nuclear transfer (SCNT). iPS allows the generation of patient specific embryonic-like stem cells that are devoid of ethical concerns and may be used for transplantation. iPS has also proven useful to create in vitro models that mimic human diseases and this could be used for high throughput drug screening. Besides, thanks to iPS we are now compelled to think of differentiation processes in a bidirectional way, which may be as well cell type and transcription factor specific. Therefore, knowledge is flourishing that will benefit Stem Cell Biology as much as unrelated disciplines. But the pace of discovery has been so quick that every technical advance has raised new issues, creating confusion. Here we will briefly define and try to answer some key questions that in our opinion will shape iPS research and application in following years.[GRAPHICS].
What problem does this paper attempt to address?